Evolent Health (NYSE:EVH) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

Evolent Health, Inc (NYSE:EVH) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.72 and traded as low as $3.61. Evolent Health shares last traded at $3.9580, with a volume of 5,080,277 shares trading hands.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent reported second-quarter adjusted earnings of $0.02 per share, compared with analysts’ expectation of a $0.01 loss and a $0.10 loss in the year-ago quarter. Evolent Health Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue rose sharply year over year, with management emphasizing continued growth, improving profitability, and stronger cash flow. The earnings call also highlighted a bullish 2027 outlook, supporting the view that Evolent’s expansion is becoming more durable. Evolent Health Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.6 billion to $2.7 billion, above the roughly $2.5 billion consensus estimate. That outlook gives investors greater confidence in Evolent’s growth trajectory. Evolent Announces Second Quarter 2026 Results
• Neutral Sentiment: Despite the improved operating performance, Evolent remains unprofitable on a GAAP basis, with a negative net margin, and analysts still project a full-year loss. Execution against the new guidance will therefore remain important.
• Negative Sentiment: The company continues to carry elevated leverage, including a debt-to-equity ratio above 2, which could limit financial flexibility if growth or cash-flow improvements fall short.

Analyst Ratings Changes

Several brokerages have recently commented on EVH. Truist Financial cut Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a report on Tuesday, June 30th. TD Cowen cut their price target on Evolent Health from $8.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Needham & Company LLC upped their price target on shares of Evolent Health from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Weiss Ratings raised shares of Evolent Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Finally, Canaccord Genuity Group raised their price objective on shares of Evolent Health from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.16.

Evolent Health Price Performance

The stock has a market capitalization of $445.20 million, a P/E ratio of -0.87 and a beta of 0.79. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.32 and a current ratio of 1.32. The stock has a 50-day simple moving average of $4.75 and a 200 day simple moving average of $3.72.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, August 6th. The technology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. Evolent Health had a negative return on equity of 3.94% and a negative net margin of 24.08%.The company had revenue of $484.50 million during the quarter, compared to the consensus estimate of $597.69 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The firm’s quarterly revenue was up 46.9% on a year-over-year basis. On average, equities analysts forecast that Evolent Health, Inc will post -0.16 earnings per share for the current fiscal year.

Institutional Trading of Evolent Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC boosted its stake in shares of Evolent Health by 4,000.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after purchasing an additional 4,000 shares during the last quarter. Strs Ohio bought a new stake in shares of Evolent Health during the first quarter worth approximately $47,000. Headlands Technologies LLC bought a new stake in shares of Evolent Health during the second quarter worth approximately $58,000. Quantbot Technologies LP bought a new stake in shares of Evolent Health during the third quarter worth approximately $88,000. Finally, Caxton Associates LLP acquired a new position in Evolent Health in the third quarter valued at approximately $93,000.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.